-
1.发明授权METHYLATED, SmD HOMOLOGOUS PEPTIDES, REACTIVE WITH THE ANTIBODIES FROM SERA OF LIVING BEINGS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS 有权甲基化SMD同源性肽的抗体从众生的血清与系统性红斑狼疮REACT
公开(公告)号：EP0944649B1
公开(公告)日：2006-10-18
申请号：EP98947487.9
申请日：1998-08-31
申请人： Innogenetics N.V.
IPC分类号： C07K14/705 , C07K16/18 , C07K16/42 , G01N33/564 , C12N15/12 , C12P21/02 , A61K38/17
CPC分类号： C07K7/08 , A61K38/00 , C07K14/001 , C07K14/4713 , C07K14/525 , C07K2319/00
摘要： The present invention relates to a method of producing certain peptides containing methylated arginines that are followed by a glycine residue and that constitute immunogenic determinants of antibodies present in sera from patients with systemic lupus erythematosus, or Epstein-Barr virus and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptides for diagnosis and treatment of systemic lupus erythematosus and related diseases, and diseases in which Epstein-Barr virus has been implicated.
-
2.发明公开METHYLATED, SmD HOMOLOGOUS PEPTIDES, REACTIVE WITH THE ANTIBODIES FROM SERA OF LIVING BEINGS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS 有权甲基化SMD同源性肽的抗体从众生的血清与系统性红斑狼疮REACT
公开(公告)号：EP0944649A1
公开(公告)日：1999-09-29
申请号：EP98947487.0
申请日：1998-08-31
申请人： INNOGENETICS N.V.
IPC分类号： G01N33 , A61K38 , A61K39 , A61P29 , A61P35 , A61P37 , C07K7 , C07K14 , C07K16 , C12N15 , C12P21 , C12R1
CPC分类号： C07K7/08 , A61K38/00 , C07K14/001 , C07K14/4713 , C07K14/525 , C07K2319/00
摘要： The present invention relates to a method of producing certain peptides containing methylated arginines that are followed by a glycine residue and that constitute immunogenic determinants of antibodies present in sera from patients with systemic lupus erythematosus, or Epstein-Barr virus and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptides for diagnosis and treatment of systemic lupus erythematosus and related diseases, and diseases in which Epstein-Barr virus has been implicated.
-
3.发明公开HUMAN FOAM CELLS AND METHODS FOR PREPARING THEM, MONOCLONAL ANTIBODIES TO SAID FOAM CELLS AND THEIR PHARMACEUTICAL AND DIAGNOSTIC USE 失效人细胞泡沫和工艺及其生产，反对泡沫细胞药物和诊断应用的单克隆抗体
公开(公告)号：EP0726942A1
公开(公告)日：1996-08-21
申请号：EP94930226.0
申请日：1994-10-26
申请人： Innogenetics N.V.
发明人： DE SMET, Walter , UNION, Ann
CPC分类号： C07K16/28 , A61K38/00 , C07K14/705 , C07K14/70525 , C07K16/2821 , C12N5/0645 , C12N2500/36 , C12N2501/01 , C12N2501/385 , Y10S530/809
摘要： The present invention relates to human foam cells generated in vitro from monocyte/macrophage related cell lines which give rise to an average intracellular cholesterol amount of at least 139+36 νg/mg cell protein as determined by HPLC, with said cholesterol being characterized by a degree of 46+6 % of esterification as determined by HPLC. The invention also relates to monoclonal antibodies selected via said foam cells and which can be used for pharmaceutical and diagnostic purposes.
-
4.发明公开
公开(公告)号：EP1240180A2
公开(公告)日：2002-09-18
申请号：EP00983355.9
申请日：2000-12-20
申请人： INNOGENETICS N.V.
发明人： UNION, Ann , MOEREELS, Henri , MEHEUS, Lydie
摘要： The present invention relates to peptides that mimic the immunogenic determinants of self-proteins recognised by autoimmune antibodies in a biological sample from patients suffering from rheumatoid arthritis (RA). More particularly, the present invention relates to citrulline-containing peptides, which react with the majority of the latter antibodies. Furthermore, the present invention relates to diagnostic tools for a more convenient and sensitive diagnosis of RA and to therapeutical methods to treat RA.
-
5.发明授权MONOCLONAL ANTIBODIES TO FOAM CELLS AND THEIR PHARMACEUTICAL AND DIAGNOSTIC USE 失效单克隆抗体的泡沫细胞药物和诊断应用
公开(公告)号：EP0726942B1
公开(公告)日：2001-12-19
申请号：EP94930226.9
申请日：1994-10-26
申请人： Innogenetics N.V.
发明人： DE SMET, Walter , UNION, Ann
IPC分类号： C12N5/08 , C07K14/705 , C07K16/28 , C12Q1/02 , C12P21/08 , C12N5/12 , A61K39/395
CPC分类号： C07K16/28 , A61K38/00 , C07K14/705 , C07K14/70525 , C07K16/2821 , C12N5/0645 , C12N2500/36 , C12N2501/01 , C12N2501/385 , Y10S530/809
摘要： The present invention relates to human foam cells generated in vitro from monocyte/macrophage related cell lines which give rise to an average intracellular cholesterol amount of at least 139+36 νg/mg cell protein as determined by HPLC, with said cholesterol being characterized by a degree of 46+6 % of esterification as determined by HPLC. The invention also relates to monoclonal antibodies selected via said foam cells and which can be used for pharmaceutical and diagnostic purposes.
-
6.发明公开SYNTHETIC PEPTIDES CONTAINING CITRULLINE RECOGNIZED BY RHEUMATOID ARTHRITIS SERA AS TOOLS FOR DIAGNOSIS AND TREATMENT 审中-公开瓜氨酸，含有合成肽，活性的血清风湿关节炎患者，诊断和治疗
公开(公告)号：EP1034186A2
公开(公告)日：2000-09-13
申请号：EP98965715.0
申请日：1998-11-30
申请人： INNOGENETICS N.V.
发明人： MEHEUS, Lydie , UNION, Ann , RAYMACKERS, Joseph
IPC分类号： C07K14/47 , C07K1/107 , C07K16/18 , A61K38/17 , G01N33/564
CPC分类号： C07K1/107 , A61K38/00 , C07K14/4713 , C07K2319/00
摘要： The present invention relates to a method of producing certain peptides containing citrulline residues that constitute immunogenic determinants of antibodies present in sera from patients with rheumatoid arthritis and wherein the presence of at least one citrulline is a prerequisite for reacting with said antibodies. The invention also relates to a method of producing said antibodies and the use of said peptides for diagnosis and treatment of rheumatoid arthritis.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
